Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Cash & Current Investments (2016 - 2025)

Marimed has reported Cash & Current Investments over the past 15 years, most recently at $8.9 million for Q4 2025.

  • Quarterly Cash & Current Investments rose 22.0% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, up 22.0% year-over-year, with the annual reading at $8.9 million for FY2025, 22.0% up from the prior year.
  • Cash & Current Investments was $8.9 million for Q4 2025 at Marimed, up from $6.6 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $34.7 million in Q1 2022 and troughed at $6.1 million in Q2 2025.
  • The 5-year median for Cash & Current Investments is $12.4 million (2022), against an average of $14.4 million.
  • Year-over-year, Cash & Current Investments surged 683.72% in 2021 and then plummeted 67.06% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $29.9 million in 2021, then crashed by 67.06% to $9.9 million in 2022, then soared by 49.42% to $14.7 million in 2023, then crashed by 50.57% to $7.3 million in 2024, then increased by 22.0% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Cash & Current Investments are $8.9 million (Q4 2025), $6.6 million (Q3 2025), and $6.1 million (Q2 2025).